Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 526

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 526
---
 | ​ | ​            | ​ |   4,547 | ​ | ​ | ​ | ​    | ​ |   4,000 | ​ | ​ |
| Class B Member Units                    | ​ | ​ | ​            | ​ |     167 | ​ | ​ | ​ | ​    | ​ |     167 | ​ | ​ |
| Additional paid-in capital              | ​ | ​ | ​            | ​ |   4,611 | ​ | ​ | ​ | ​    | ​ |   5,158 | ​ | ​ |
| Accumulated deficit                     | ​ | ​ | ​            | ​ | -25,119 | ​ | ​ | ​ | ​    | ​ | -20,135 | ​ | ​ |
| Total members’ deficit                  | ​ | ​ | ​            | ​ | -15,794 | ​ | ​ | ​ | ​    | ​ | -10,810 | ​ | ​ |
| TOTAL LIABILITIES AND MEMBERS’ DEFICIT  | ​ | ​ | ​            | $ |   2,242 | ​ | ​ | ​ | ​    | $ |   6,843 | ​ | ​ |

The accompanying notes are an integral part of these financial statements. F-71

TABLE OF CONTENTS

LIMINATUS PHARMA, LLC STATEMENTS OF OPERATIONS
(in thousands, except member unit and per member unit data)

| ​                                                                    
 ​                                                                    | ​ 
 ​ | ​ 
 ​ | Year ended December 31, 
 2023                    |   |            |   | ​ | ​ | 2022 |   |            |   | ​ 
 ​ |
|:---------------------------------------------------------------------|:--|:--|:------------------------|:--|-----------:|:--|:--|:--|:-----|:--|-----------:|:--|:--|
| Operating expenses:                                                  | ​ | ​ | ​                       | ​ |          ​ | ​ | ​ | ​ | ​    | ​ |          ​ | ​ | ​ |
| General and administrative                                           | ​ | ​ | ​                       | $ |      1,062 | ​ | ​ | ​ | ​    | $ |        856 | ​ | ​ |
| Research and development                                             | ​ | ​ | ​                       | ​ |      3,757 | ​ | ​ | ​ | ​    | ​ |      1,853 | ​ | ​ |
| Total